E Fund Management Co. Ltd. Invests $1.42 Million in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

E Fund Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTXFree Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 189,432 shares of the company’s stock, valued at approximately $1,421,000.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD acquired a new position in Kyverna Therapeutics during the first quarter worth $23,093,000. Jennison Associates LLC acquired a new position in Kyverna Therapeutics during the first quarter worth $34,743,000. Janus Henderson Group PLC acquired a new position in Kyverna Therapeutics during the first quarter worth $15,041,000. TD Asset Management Inc acquired a new position in Kyverna Therapeutics during the second quarter worth $677,000. Finally, Vanguard Group Inc. acquired a new position in Kyverna Therapeutics during the first quarter worth $6,563,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Kyverna Therapeutics Stock Performance

KYTX stock opened at $6.66 on Wednesday. The company’s 50-day simple moving average is $8.06 and its 200 day simple moving average is $13.97. Kyverna Therapeutics, Inc. has a 52 week low of $6.30 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTXGet Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.03. As a group, analysts anticipate that Kyverna Therapeutics, Inc. will post -3.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on KYTX. JPMorgan Chase & Co. lowered their target price on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. HC Wainwright decreased their price objective on shares of Kyverna Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.40.

Check Out Our Latest Report on KYTX

Kyverna Therapeutics Company Profile

(Free Report)

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

Featured Articles

Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTXFree Report).

Institutional Ownership by Quarter for Kyverna Therapeutics (NASDAQ:KYTX)

Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.